Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

.

July 10, 2026

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.
Representative: Hiroshi Matsumori, President and CEO
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)
Inquiries: Kenji Otsuga, Executive Officer, CFO
(Telephone Number: +81-76-421-5665)

Notice Regarding the Acquisition of Treasury Shares and the Purchase of Treasury Shares Through Off-Auction Own Share Repurchase Transaction (ToSTNeT-3)

(Purchase of treasury shares pursuant to the Articles of Incorporation in accordance with Article 459, Paragraph 1 of the Companies Act and purchase of treasury shares through Off-Auction Own Share Repurchase Trading (ToSTNeT-3))

Daito Pharmaceutical Co., Ltd. (the "Company") resolved at the Board of Directors meeting held on July 10, 2026, to purchase its own shares pursuant to the Articles of Incorporation in accordance with Article 459, Paragraph 1 of the Companies Act, and determined the specific method of purchase as follows.

1. Reason for acquisition of treasury shares

The Company will acquire treasury shares as part of its capital policy under the Medium-Term Management Plan, with the aim of enhancing shareholder returns and improving capital efficiency.

2. Method of acquisition of treasury shares

The Company will place an order through the Tokyo Stock Exchange’s off-auction own share repurchase transaction (ToSTNet-3) at 8:45 a.m. on July 13, 2026, at 1,250 yen, the closing price of the Company’s shares as of today (July 10, 2026), including the final special quote. No change will be made to other trading system or trading time. The buy order will be valid only during the aforementioned trading time.

3. Details of acquisition

(1) Class of shares to be acquired:	Common stock of the Company
(2) Total number of shares to be acquired:	Up to 500,000 shares (Equivalent to 1.7% of the total number of shares issued, excluding treasury shares)
(3) Total acquisition cost of shares:	Up to 625,000,000 yen
(4) Disclosure of acquisition results:	The results of acquisition will be announced after the completion of the transaction at 8:45 a.m. on July 13, 2026.

Notes:

1 The number of shares to be acquired will not be changed. However, depending on market conditions and other factors, some or all of the acquisition may not be executed.

2 The purchase will be made against sell orders corresponding to the number of shares scheduled to be acquired.

Reference: Treasury shares held as of June 30, 2026

Total number of shares issued (excluding treasury shares): 28,838,162 shares
Number of treasury shares: 16,718 shares

Note: The above number of treasury shares does not include 94,340 shares of the Company held in trust under the stock delivery trust for Board Directors.

End